Laboratory Corporation of America Holdings (LH) Earns Daily News Impact Score of 0.18

News articles about Laboratory Corporation of America Holdings (NYSE:LH) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Laboratory Corporation of America Holdings earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.6432533376978 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Shares of Laboratory Corporation of America Holdings (NYSE:LH) traded up 0.25% during mid-day trading on Monday, hitting $153.68. The company had a trading volume of 291,570 shares. Laboratory Corporation of America Holdings has a 1-year low of $119.51 and a 1-year high of $154.82. The company has a 50-day moving average price of $142.43 and a 200-day moving average price of $138.87. The company has a market capitalization of $15.72 billion, a price-to-earnings ratio of 21.11 and a beta of 0.93.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its earnings results on Tuesday, April 25th. The medical research company reported $2.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.19 by $0.03. The company had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.41 billion. Laboratory Corporation of America Holdings had a return on equity of 16.99% and a net margin of 7.76%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the business posted $2.02 EPS. On average, equities analysts anticipate that Laboratory Corporation of America Holdings will post $9.43 EPS for the current year.

Several research firms have recently weighed in on LH. Credit Suisse Group cut Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 price target for the company. in a research note on Thursday. They noted that the move was a valuation call. BidaskClub upgraded Laboratory Corporation of America Holdings from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 28th. Zacks Investment Research cut Laboratory Corporation of America Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. Jefferies Group LLC decreased their price target on Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating for the company in a research note on Friday, April 28th. Finally, ValuEngine cut Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Saturday, June 3rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $154.35.

TRADEMARK VIOLATION WARNING: This news story was published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2723627/laboratory-corporation-of-america-holdings-lh-earns-daily-news-impact-score-of-0-18.html.

In other Laboratory Corporation of America Holdings news, Director Jean-Luc Belingard sold 992 shares of Laboratory Corporation of America Holdings stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $142.19, for a total transaction of $141,052.48. Following the completion of the transaction, the director now owns 32,935 shares in the company, valued at approximately $4,683,027.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Lance Berberian sold 3,613 shares of Laboratory Corporation of America Holdings stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $139.84, for a total value of $505,241.92. Following the transaction, the senior vice president now owns 5,789 shares of the company’s stock, valued at approximately $809,533.76. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback


Leave a Reply

© 2006-2017 Ticker Report. Google+.